Interferon-g (IFN-g) induces tryptophan catabolism in HEp-2 cells, possibly via stimulation of host cell indoleamine-2,3-dioxygenase activity, in a dose-dependent (12.5 -1600 U/mL) fashion after 24 h, resulting in a 99% conversion to its metabolites at 1600 U/mL. Replication of Chlamydia pneumoniae isolates A-03 and BAL-16 was inhibited in HEp-2 cells following treatment with 50 and 100 U/mL IFN-g, respectively; however, addition of excess L-tryptophan (200 mg/mL) to monolayers infected with C. pneumoniae resulted in unrestricted growth of both isolates up to 1600 U/mL IFNg. C. pneumoniae could be recovered from IFN-g -treated monolayers, indicating the potential for this bacterium to undergo an altered life cycle, in vitro, analogous to that described in detail for Chlamydia trachomatis. The ability of C. pneumoniae to persist in host tissue despite an immunologic response would be an important attribute in order to cause or exacerbate chronic infections.
Chlamydia pneumoniae causes acute respiratory disease, inmal chlamydial life cycle. Removal of the IFN-g pressure, accompanied with the return of normal tryptophan levels, cluding pneumonia, bronchitis, sinusitis, and pharyngitis [1, 2] , and has been implicated in chronic disease states, such as allows for the resumption of the normal chlamydial life cycle. This is an intriguing theory of a mechanism for chlamydial atherosclerosis [3] , asthma [4] , and sarcoidosis [5] . The role of C. pneumoniae in atherosclerosis is unclear; however, nusurvival in host tissue and may explain the ability of this organism to cause chronic infection with the resulting inflammatory merous studies have reported detection of this bacterium in atheromatous lesions [6 -8] , including a study from this laborachanges noted in C. trachomatis disease. The ability of Chlamydia species to survive in host tissue tory on the isolation of C. pneumoniae from coronary atheroma of a patient with severe coronary artery disease [9] . A second would be a necessary attribute for this bacterium to either cause or exacerbate the inflammatory reactions seen in atheromatous isolate from a carotid artery atheroma has recently been reported [10] . The ability of C. pneumoniae to cause persistent plaques and other chronic infections. We have previously shown that growth of C. pneumoniae is restricted in HEp-2 respiratory infections in humans has been documented [11 -13] ; however, the mode of survival in host tissue, despite apcells pretreated with IFN-g and that the addition of tumor necrosis factor-a may enhance the inhibitory activity of IFNpropriate antibiotic therapy, is not known.
Interferon-g (IFN-g) -mediated activation of host cells to g [16] . The present study sought to further characterize this cytokine effect in terms of establishing the role of tryptophan restrict multiplication of chlamydiae has been proposed as a mechanism for establishing persistent Chlamydia trachomatis catabolism in the growth restriction of a coronary and a respiratory isolate of C. pneumoniae. An attempt was also made to infection in vivo. Byrne and colleagues [14, 15] have presented a detailed description of IFN-g -mediated persistence of C.
determine if C. pneumoniae could be recovered from IFN-gtreated monolayers, thus indicating the potential to undergo an trachomatis in cell culture. This mechanism involves the induction of host cell indoleamine-2,3-dioxygenase (IDO) with subinterruptive life cycle, in vitro, similar to that seen with C. trachomatis. sequent degradation of tryptophan to its metabolites, thus depriving the bacterium of levels of this amino acid sufficient for growth. In vitro, this results in the formation of large aberrant Materials and Methods replicative forms, representing an interruptive stage in the nor-respiratory isolate from a patient with pneumonia, was obtained Effects of tryptophan-depleted medium on C. pneumoniae growth. Tryptophan-depleted medium was prepared by the addifrom Margaret Hammerschlag (Health Sciences Center at Brooktion of individual amino acids, excluding tryptophan, according to lyn, Brooklyn, NY). Both isolates were passaged in HEp-2 cell the recipe for Iscove's modified Eagle medium. This was then monolayers in medium containing 1.0 mg/mL cyclohexamide and supplemented with 10% fetal bovine serum, which had been prethen harvested, aliquoted, and stored at 070ЊC until needed.
viously dialyzed for 48 h to remove all tryptophan. Nonessential Major histocompatibility class II response of HEp-2 cells to amino acids and antibiotics were then added as described above. IFN-g. Flat-bottomed, 24-well tissue culture plates (Costar) with An aliquot was resupplemented with 16.0 mg/mL L-tryptophan, coverslips were seeded with 1.0 mL of HEp-2 cell suspension and representing the normal concentration in control medium. Aliquots allowed to adhere for 24 h prior to use in experiments. Cells were (100 mL) of C. pneumoniae A-03 and BAL-16 stock preparation then treated with 100 U/mL IFN-g (Promega, Madison, WI) and (10 5 ifu/mL) were added to wells of a 24-well plate containing a incubated for 24, 48, and 72 h. At each time period, cells from coverslip with a confluent HEp-2 cell monolayer. Plates were then three wells were washed, trypsinized, harvested, and pelleted. Cells centrifuged at 800 g for 1 h and followed by an additional 30-min (200 mL) and PBS-azide (800 mL) were added to each microcentriincubation at 37ЊC. Wells were then aspirated, replaced with fresh fuge tube. These tubes were centrifuged, and 20 mL of HLA-DRtryptophan-depleted medium containing 1.0-16.0 mg/mL L-tryptophycoerythrin antibody (HLA-DR-PE; Becton Dickinson, Sparks, phan, and incubated for 72 h at 37ЊC. Monolayers were then fixed MD) was added to the pellets and mixed. Phosphate buffer (800 for 10 min in methanol, stained, and examined by epifluorescence mL) was added, and the tubes were centrifuged. seeded with HEp-2 cells and incubated for 24 h at 37ЊC. Aliquots Aliquots (100 mL) of C. pneumoniae A-03 and BAL-16 stock (100 mL) of C. pneumoniae A-03 and BAl-16 stock preparation preparations (10 5 inclusion-forming units [ifu]/mL) were added to (10 5 ifu/mL) were added to these monolayers. All plates were then wells of 24-well plates containing a coverslip with a confluent centrifuged at 800 g for 1 h, followed by an additional 30-min HEp-2 cell monolayer. Plates were then centrifuged at 800 g for incubation at 37ЊC. Wells were aspirated and replaced with fresh 1 h, followed by an additional 30-min incubation at 37ЊC. Wells medium containing 1.0-16.0 mg/mL L-tryptophan. Plates were were aspirated and covered with fresh medium containing 0-1600 incubated for 72 h at 37ЊC, after which all monolayers were supple-U of IFN-g/mL (Promega). All plates were incubated for 72 h at mented with fresh growth medium containing normal concentra-37ЊC, and in some experiments, supernatants were aspirated and tions of L-tryptophan. At 48, 72, and 96 h of incubation at 37ЊC, monolayers assayed for tryptophan catabolism measurements as wells were aspirated. The monolayers were fixed for 10 min in described below. Coverslips were then removed, stained with a methanol, stained, and examined by epifluorescence microscopy Chlamydia species-specific anti-lipopolysaccharide, fluorescein (2001) for the presence or absence of inclusion bodies. isothiocyanate-labeled antibody reagent (Pathfinder; Sanofi DiagIn one set of experiments, at the end of the 96-h incubation nostics Pasteur, Chaska, MN), and examined by epifluorescence period, cells were harvested and inoculated onto a fresh HEp-2 microscopy (2001) for the presence or absence of inclusion body monolayer for detection of infectivity. After further incubation for formation. Identical experiments were also done in the presence 48 h, monolayers were then fixed for 10 min in methanol, stained, of excess (200 mg/mL) L-tryptophan or D-tryptophan (Sigma, St.
and examined by epifluorescence (2001) for the presence or abLouis). All experiments were repeated four times.
sence of inclusion bodies.
Measurement of tryptophan catabolism. Catabolism of trypto-
Recovery experiments of C. pneumoniae from IFN-g-treated phan to its metabolites in infected and uninfected HEp-2 cells was HEp-2 cells were similar to those described above, with the exception measured by paper chromatography as described by Pfefferkorn of the addition of IFN-g, 0-1600 U/mL, to normal growth medium [17] . After each well was aspirated, cell monolayers were overlaid prior to inoculation with C. pneumoniae A-03 or BAL-16. with pulse medium containing 0.025 mM L-tryptophan and 1.0 mCi/mL L-(5- In contrast, L-tryptophan completely reversed the inhibitory effect of IFN-g treatment, and C. pneumoniae could replicate up to 1600 U/mL. Growth of C. pneumoniae in tryptophan-depleted medium. To study direct involvement of tryptophan in the inhibition of C. pneumoniae growth in HEp-2 cells, experiments were done in tryptophan-depleted medium resupplemented with increasing concentrations of L-tryptophan. Table 2 indicates that C. pneumoniae did not grow in tryptophan-depleted medium or in medium resupplemented with 1.0 -11.5 mg/mL L-tryptophan. However, on addition of L-tryptophan at §12.0 mg/mL, C.
HEp-2 cells. Cells were treated with increasing concentrations of pneumoniae replication was detectable by inclusion body for-IFN-g, and after 72-h incubation, monolayers were treated with pulse medium for 4 h and tryptophan catabolism was measured.
mation. Both isolates A-03 and BAL-16 showed identical requirements for concentrations of L-tryptophan in the medium.
Recovery of C. pneumoniae from tryptophan-depleted and IFN-g, 63% of the tryptophan had been catabolized by 48 h, IFN-g -treated HEp-2 monolayers.
To determine if C. pneuwhereas at 1600 U/mL, a 99% tryptophan catabolism rate was moniae could be cultured from monolayers in which growth observed. Identical results were seen when monolayers infected had been restricted by tryptophan depletion or IFN-g treatment, with C. pneumoniae were stimulated with increasing concentra-C. pneumoniae -infected monolayers were resupplied with nortions of IFN-g. however, recovery from these monolayers was possible followpneumoniae were inhibited from forming detectable inclusion ing 72 and 96 h of incubation in normal growth medium. The bodies in IFN-g -treated HEp-2 cells. C. pneumoniae isolate resulting inclusions formed by these recovered bacteria were A-03 failed to produce detectable inclusions at 50 U/mL not infectious when applied to fresh HEp-2 monolayers. Addi-IFN-g, whereas the minimum inhibitory concentration for tion of L-tryptophan to tryptophan-depleted medium at concen-BAL-16 was 100 U/mL. These results were confirmed during trations §12.0 mg/mL gave results similar to those seen with three separate experiments.
control medium, in that inclusion formation was seen 48 h after To determine the effect of excess tryptophan on C. pneumothe addition of fresh medium and the inclusions that formed at 96 h contained infectious elementary bodies (EB). niae replication, similar experiments were done in the presence NOTE. 0 denotes absence of inclusion bodies; / denotes presence of ‡ HEp-2 cells grown in tryptophan-depleted medium infected with C. pneuinclusion bodies in ú90% of monolayer. moniae.
* 96 h after addition of fresh medium, monolayers were harvested and inoculated onto fresh HEp-2 monolayers for detection of infectivity.
† HEp-2 cells grown in control medium infected with C. pneumoniae.
Similar experiments to determine if C. pneumoniae could be recovered from IFN-g -treated HEp-2 cells (table 4) indi-96 h of incubation. Of interest, both isolates were capable of cated that monolayers infected with A-03 were initially inhibreplication at all IFN-g concentrations at 72 or 96 h after ited at 50 U/mL and that 100 U/mL IFN-g was required to the addition of fresh medium; however, inclusions containing inhibit BAL-16. Upon the addition of fresh growth medium, infectious EB were seen only up to 200 U/mL IFN-g. neither isolate produced detectable inclusion bodies after 48 h of incubation; however, inclusions were seen following 72 and Discussion
Chlamydiae are common pathogens, causing a broad spec- e., 400 -1600 U/mL) or the low tryptophan concenreplication. Catabolism of tryptophan in HEp-2 cells appears to be L-tryptophan specific, in that growth inhibition studies in trations (õ7.0 mg/mL) used in the recovery experiments, ú96 h is required for a full recovery. It is also enticing to correlate the presence of excess D-tryptophan had no effect, whereas excess L-tryptophan completely reversed the effect of IFN-g -L-tryptophan levels with levels of IFN-g needed to inhibit replication; however, no direct measurements were made in mediated growth inhibition of both isolates tested here. This would suggest that IFN-g treatment induces an L-tryptophanthese monolayers. It is clear that C. pneumoniae exhibits susceptibilities to specific IDO activity in HEp-2 cells and that IDO induction is responsible for C. pneumoniae inhibition, presumably through IFN-g treatment and L-tryptophan concentrations similar to those described in detail for C. trachomatis, and this would reductions in available intracellular tryptophan levels. However, no direct evidence of IDO induction was provided in this appear to offer an in vitro correlate to what might occur in infected tissue. If Chlamydia species in general and C. pneustudy.
Slight differences in IFN-g susceptibility between the 2 moniae in particular do participate in long-term, chronic, inflammatory-type disease states, they must possess some mechaisolates tested here were seen (50 U/mL for A-03 vs. 100 U/mL for BAL-16); however, no differences were seen when nism of survival in host tissue for extended periods of time.
Although no replicative form of Chlamydia species other than tryptophan resupplementation experiments were done in tryptophan-depleted medium. This may reflect distinct biologic feathose considered normal have been seen in host tissue to date, this does not preclude the possibility. Evidence continues to tures of each isolate. Alternatively, this could be explained either by lower sensitivities of detection with the tryptophan mount showing a strong physical association of C. pneumoniae and chronic infections, such as atherosclerosis, in humans. resupplementation assays or by IFN-g possibly stimulating other undetected inhibition pathways in HEp-2 cells, of which Studies in this laboratory are underway to determine whether growth-inhibitory characteristics of C. pneumoniae in response A-03 is more susceptible. In addition, it appears that C. pneumoniae has a slightly decreased susceptibility to IFN-g treatto IFN-g pressure similar to those described here occur in a more relevant cell line, namely coronary artery smooth muscle ment of HEp-2 cells compared with that of C. trachomatis A/ Har-13 in HeLa 229 cells, which required only 2.0 ng/mL (20.0 cells. True causality must await further studies; however, the data presented here provide a potential mechanism of bacterial U/mL) for complete inhibition of growth [15] . Infectious C. trachomatis EB were not present at this concentration even at persistence in host tissue. 72 h following the removal of IFN-g.
C. pneumoniae requires exogenous supplies of L-tryptophan
